This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Early Winners & Losers

Human Genome also said it has begun dosing in a late-phase trial of its hepatitis C treatment Albuferon, in combination with ribavirin, on strong interim results from a phase IIb study. Swiss drugmaker Novartis (NVS - Get Report) is developing the product with Human Genome. The latter was up 27 cents, or 2.5%, to $11.23. Novartis shares were recently adding 18 cents to $55.50.

Komag (KOMG) was higher after the San Jose, Calif,-based maker of data-storage disks said it will supply disk-drive maker Seagate (STX - Get Report) with aluminum substrates in addition to its existing media supply agreement. Komag shares were rising 69 cents, or 2.1%, to $33.50. Seagate stock was unchanged.

Bitstream (BITS), which develops software for fonts, browsing and publishing, slid on disappointing fourth-quarter results. The Cambridge, Mass., company whittled its fourth-quarter profit down to $630,000, or 6 cents a share, from last year's $788,000, or 8 cents a share. Revenue was up 20% to $5.5 million. Shares were losing $1.38, or 13.4%, to $8.89.

Transmeta (TMTA) widened its fourth-quarter losses to $15.9 million, or 8 cents a share, from $2.1 million, or a penny a share, a year ago. The Santa Clara, Calif., semiconductor company's sales plummeted to $2.4 million from $13.3 million last year. Two analysts were looking for 6-cent losses on $3 million in revenue. Shares were dropping 6 cents, or 7.2%, to 81 cents.

Autodesk (ADSK - Get Report) fell after the San Rafael, Calif., technical-software company announced it will restate its financials downward from fiscal years 2003 through 2006, having completed its stock-option grant investigation. The company estimates pretax, noncash charges will range between $38 million and $45 million for stock-option expenses over the past 18 years, with an estimated $23 million to $26 million contained in the 2003-06 period. The remainder will be recorded for year-end 2002. Shares were down $2.35, or 5.8%, to $38.45.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ADSK $61.37 0.00%
DECK $58.65 0.00%
NVS $76.84 0.00%
STX $20.48 0.00%
AAPL $93.64 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs